<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: substantially", fill: "#e7feff"},
{source: "2: substantially", target: "2: future will", fill: "#e7feff"},
{source: "2: future will", target: "2: from royalties based on sales", fill: "#e7feff"},
{source: "2: from royalties based on sales", target: "2: CellCept ", fill: "#e7feff"},
{source: "2: CellCept ", target: "2: profitability", fill: "#e7feff"},
{source: "2: substantially", target: "4: inception through", fill: "#50404d"},
{source: "4: inception through", target: "4: December ", fill: "#50404d"},
{source: "4: December ", target: "4: incurred cumulative losses from", fill: "#50404d"},
{source: "4: incurred cumulative losses from", target: "4: operations", fill: "#50404d"},
{source: "4: inception through", target: "5: primarily from", fill: "#0067a5"},
{source: "5: primarily from", target: "5: administrative costs", fill: "#0067a5"},
{source: "5: administrative costs", target: "5: operations", fill: "#0067a5"},
{source: "5: operations", target: "5: clinical development", fill: "#0067a5"},
{source: "5: clinical development", target: "5: CellCept ", fill: "#0067a5"},
{source: "5: CellCept ", target: "5: indications", fill: "#0067a5"},
{source: "5: primarily from", target: "17: successfully manage", fill: "#e9d66b"},
{source: "17: successfully manage", target: "17: collaboration", fill: "#e9d66b"},
{source: "17: collaboration", target: "17: development", fill: "#e9d66b"},
{source: "17: development", target: "17: commercialization", fill: "#e9d66b"},
{source: "17: commercialization", target: "17: indications", fill: "#e9d66b"},
{source: "17: successfully manage", target: "23: applications", fill: "#f78fa7"},
{source: "23: applications", target: "23: regulatory approval", fill: "#f78fa7"},
{source: "23: regulatory approval", target: "23: CellCept ", fill: "#f78fa7"},
{source: "23: CellCept ", target: "23: indications", fill: "#f78fa7"},
{source: "23: indications", target: "23: ultimate decision", fill: "#f78fa7"},
{source: "23: ultimate decision", target: "23: appropriate regulatory authorities", fill: "#f78fa7"},
{source: "23: applications", target: "35: regulatory", fill: "#0f52ba"},
{source: "35: regulatory", target: "35: connection with", fill: "#0f52ba"},
{source: "35: connection with", target: "35: preapproval communications", fill: "#0f52ba"},
{source: "35: preapproval communications", target: "35: CellCept ", fill: "#0f52ba"},
{source: "35: CellCept ", target: "35: agreement", fill: "#0f52ba"},
{source: "35: regulatory", target: "START_HERE", fill: "#0f52ba"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genentech">Genentech</a></td>
      <td>Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pemphigus">Pemphigus</a></td>
      <td>Pemphigus ( or ) is a rare group of blistering autoimmune diseases that affect the skin and mucous membranes. The name is derived from the Greek root pemphix, meaning "pustule".In pemphigus, autoantibodies form against desmoglein, which forms the "glue" that attaches adjacent epidermal cells via attachment points called desmosomes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mobile_phone">Mobile phone</a></td>
      <td>A mobile home (also known as a house trailer, park home, trailer, or trailer home) is a prefabricated structure, built in a factory on a permanently attached chassis before being transported to site (either by being towed or on a trailer). Used as permanent homes, or for holiday or temporary accommodation, they are often left permanently or semi-permanently in one place, but can be moved, and may be required to move from time to time for legal reasons.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Autoimmune_autonomic_ganglionopathy">Autoimmune autonomic ganglionopathy</a></td>
      <td>Autoimmune autonomic ganglionopathy (AAG) is a rare form of dysautonomia in which the patient’s immune system produces ganglionic anti-nicotinic acetylcholine receptor (AChR) antibodies, inhibiting ganglionic AChR currents and impairing transmission in autonomic ganglia. Symptoms onset can be acute, subacute or gradual.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chugai_Pharmaceutical_Co.">Chugai Pharmaceutical Co.</a></td>
      <td>Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_geographical_indications_in_India">List of geographical indications in India</a></td>
      <td>A geographical indication (GI) is a name or sign used on certain products which corresponds to a specific geographical location or origin (e.g., a town, region, or country). India, as a member of the World Trade Organization (WTO), enacted the Geographical Indications of Goods (Registration and Protection) Act, 1999 has come into force with effect from 15 September 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Indication_(medicine)">Indication (medicine)</a></td>
      <td>In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Indication_of_interest">Indication of interest</a></td>
      <td>An indication of interest (IOI), sometimes expression of interest (EOI), is an expression in finance that demonstrates a buyer's non-binding interest in buying a security in the stock market, often before it is available for purchase. IOIs are not required, but when a firm decides to issue one, they are primarily used on two occasions: before an IPO, and before an institution places a block trade.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Geographical_Indications_of_Goods_(Registration_and_Protection)_Act,_1999">Geographical Indications of Goods (Registration and Protection) Act, 1999</a></td>
      <td>The Geographical Indications of Goods (Registration and Protection) Act, 1999 (GI Act) is a sui generis Act of the Parliament of India for protection of geographical indications in India. India, as a member of the World Trade Organization (WTO), enacted the Act to comply with the Agreement on Trade-Related Aspects of Intellectual Property Rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Geographical_indications_and_traditional_specialities_in_the_European_Union">Geographical indications and traditional specialities in the European Union</a></td>
      <td>Three European Union schemes of geographical indications and traditional specialties, known as protected designation of origin (PDO), protected geographical indication (PGI), and traditional specialities guaranteed (TSG), promote and protect names of agricultural products and foodstuffs. Products registered under one of the three schemes may be marked with the logo for that scheme to help identify those products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contraindication">Contraindication</a></td>
      <td>In medicine, a contraindication is a condition that serves as a reason not to take a certain medical treatment due to the harm that it would cause the patient.  Contraindication is the opposite of indication, which is a reason to use a certain treatment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Aspreva Pharmaceuticals CORP      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business      We anticipate that <font color="blue">substantially</font> all of our revenue for the foreseeable     <font color="blue">future will</font> be <font color="blue">from royalties based on sales</font> of <font color="blue">CellCept </font>and we may not be     able to sustain our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We were <font color="blue">incorporated</font> in 2001 and have a limited operating history</td>
    </tr>
    <tr>
      <td>Since our     <font color="blue">inception through</font> <font color="blue">December </font>31, 2005, we have <font color="blue">incurred cumulative losses from</font>     <font color="blue">operations</font> of dlra5dtta5 million</td>
    </tr>
    <tr>
      <td>Our losses to date have resulted <font color="blue">primarily from</font>     general  and <font color="blue"><font color="blue">administrative</font> costs</font> relating to our <font color="blue">operations</font> and costs     related to the <font color="blue">clinical <font color="blue">development</font></font> of <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> the terms of our <font color="blue"><font color="blue">agreement</font> with</font> Roche, commencing <font color="blue">April     </font>1,  2005, we <font color="blue">became entitled</font> to a <font color="blue">royalty based on</font> an equal sharing of     <font color="blue">incremental net sales</font> of <font color="blue">CellCept </font>in non-transplant <font color="blue"><font color="blue">indication</font>s</font> above a     negotiated baseline less a <font color="blue">distribution</font> fee, payable on a quarterly basis</td>
    </tr>
    <tr>
      <td>This baseline was <font color="blue">originally set</font> in July 2003 at CHF 134 million, and is     subject to an <font color="blue">annual <font color="blue">price index adjustment</font></font></td>
    </tr>
    <tr>
      <td>In July 2005, <font color="blue">Roche and <font color="blue">Aspreva     </font></font>agreed that the baseline for 2005 would be CHF 123 million, after taking     <font color="blue">into account</font> the <font color="blue">price index adjustment</font> and, for the time being, excluding     Japan  as  a  <font color="blue">licensed territory under</font> the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Although we were     profitable for 2005, future operating results and <font color="blue">profitability</font> are not     certain and we may not sustain our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate from period</font> to period for a number of     reasons</td>
    </tr>
    <tr>
      <td>In budgeting our operating expenses, some of which are fixed in the     short term, we assume that <font color="blue">revenues will continue</font> to grow</td>
    </tr>
    <tr>
      <td>Even a <font color="blue">relatively</font>     small <font color="blue">revenue shortfall</font> or a small increase in operating <font color="blue">expenses may</font> cause     our results to be below <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">revenue shortfall</font> or increase in     operating expenses could arise from any number of factors including:         •     lower than expected <font color="blue">revenues on commercial sales</font> <font color="blue">of CellCept</font>;       •     higher than expected operating <font color="blue">expenses as</font> we further develop <font color="blue">CellCept </font>for     autoimmune <font color="blue"><font color="blue">indication</font>s</font>, seek <font color="blue">additional</font> <font color="blue"><font color="blue">collaboration</font>s</font> and operate as a     public company;       •     higher than expected levels of marketing expenses and the expenses of     <font color="blue">potentially launching</font> <font color="blue">CellCept </font>and any <font color="blue">future products</font> for our targeted     <font color="blue"><font color="blue">indication</font>s</font>; and       •     <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates</font></td>
    </tr>
    <tr>
      <td>We anticipate that <font color="blue">substantially</font> all of our revenue for the foreseeable     <font color="blue">future will</font> be <font color="blue">from royalties based on sales</font> of <font color="blue">CellCept </font>pursuant to our     <font color="blue"><font color="blue">agreement</font> with</font> Roche</td>
    </tr>
    <tr>
      <td>Our revenue is <font color="blue">dependent on</font> Roche and our mutual     ability  to  track  product  sales arising from the use of <font color="blue">CellCept </font>by     transplant  patients</td>
    </tr>
    <tr>
      <td>The <font color="blue">methodology</font> for <font color="blue">accurately tracking sales</font> of     <font color="blue">CellCept </font>that has been agreed to may be a source of <font color="blue">dispute with</font> Roche,     <font color="blue">which <font color="blue">may negatively affect</font></font> our revenue and our <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       If we and Roche are unable to <font color="blue"><font color="blue">successfully</font> manage</font> our <font color="blue">collaboration</font>, the     <font color="blue">development</font> and <font color="blue">commercialization</font> of CelICept for autoimmune <font color="blue"><font color="blue">indication</font>s</font> may     be delayed or prevented</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaboration</font> with Roche involves a <font color="blue">complex sharing</font> of <font color="blue">control over</font>     decisions, responsibilities, costs and benefits</td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>and promotional     <font color="blue">activities</font> related to <font color="blue">CellCept </font>in the autoimmune <font color="blue"><font color="blue">indication</font>s</font> are <font color="blue">approved by</font>     a joint committee, consisting of an equal number of our <font color="blue">representatives</font> and     Rocheapstas <font color="blue">representatives</font></td>
    </tr>
    <tr>
      <td>In the event that the joint committee is unable to     reach  <font color="blue">consensus</font>  on  an issue, the dispute will be referred to senior     <font color="blue">management</font> of both parties</td>
    </tr>
    <tr>
      <td>Unless and until senior <font color="blue">management</font> reaches     <font color="blue">agreement</font> on such dispute, neither party will have the right to implement     any changes to the <font color="blue">status quo</font> that would result <font color="blue">from resolution</font> of such     matter</td>
    </tr>
    <tr>
      <td>Although we are responsible for     compiling and preparing all <font color="blue"><font color="blue">application</font>s</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">CellCept </font>    in autoimmune <font color="blue"><font color="blue">indication</font>s</font>, Roche has the <font color="blue">ultimate decision</font> making authority     to submit these <font color="blue"><font color="blue">application</font>s</font> to the <font color="blue">appropriate <font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>If     Roche does not approve the <font color="blue">application</font> we prepared, or requires that we     revise or modify the <font color="blue">application</font>, this could result in delays in receipt of     <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>In addition, Roche may develop and <font color="blue">commercialize</font>,     <font color="blue">either alone</font> or with others, products that are similar to, or <font color="blue">competitive</font>     with, CellCept</td>
    </tr>
    <tr>
      <td>Roche may also change the focus of its <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts and <font color="blue">dedicate fewer resources</font> to <font color="blue">CellCept </font>or our     <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>If we do not satisfy our <font color="blue"><font color="blue">obligations</font> under</font> the Roche <font color="blue">agreement</font> or if the     <font color="blue">agreement</font> is terminated we may be forced to limit or cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font> with</font> Roche requires us to <font color="blue">use <font color="blue">commercially</font> reasonable efforts</font>     to  conduct  three  <font color="blue"><font color="blue">clinical trial</font> programs</font> for <font color="blue">CellCept </font>in autoimmune     <font color="blue"><font color="blue">indication</font>s</font> pursuant to an agreed upon <font color="blue">development</font> plan</td>
    </tr>
    <tr>
      <td>Roche may allege     that we are in breach of a material <font color="blue">obligation under</font> our <font color="blue">agreement</font> and seek     to litigate the <font color="blue">allegation</font></td>
    </tr>
    <tr>
      <td>If Roche is successful in <font color="blue">such <font color="blue">litigation</font></font>, <font color="blue">Roche     </font>may either be <font color="blue">awarded damages based upon such breach</font> or the <font color="blue">agreement</font> might     be terminated</td>
    </tr>
    <tr>
      <td>After 2011, <font color="blue">either party may terminate</font> the <font color="blue">agreement</font> if there     is a lack of non-transplant sales over the baseline for a <font color="blue">prolonged period</font></td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">CellCept </font>is <font color="blue">withdrawn from</font> or recalled in any <font color="blue">given country</font>,     <font color="blue">either party may terminate</font> the <font color="blue"><font color="blue">agreement</font> with</font> respect to that country</td>
    </tr>
    <tr>
      <td>If     the <font color="blue">agreement</font> is terminated in its entirety or in a <font color="blue">given country</font> we may be     forced to limit or cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font> with</font> Roche <font color="blue">contains provisions</font> requiring us to <font color="blue">comply with</font>     <font color="blue">applicable laws</font> and <font color="blue">regulations</font>, including <font color="blue"><font color="blue">restrictions</font> on</font> the promotion of     <font color="blue">approved drugs</font> for <font color="blue">off label uses</font></td>
    </tr>
    <tr>
      <td>If it were determined by the FDA or other     <font color="blue">regulatory</font>  authority that we violated the rules relating to off label     promotion in <font color="blue">connection with</font> our pre-approval <font color="blue">communications</font> regarding     CellCept,  we  may  be deemed by Roche to be in material breach of the     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If we fail to cure any material breach of the <font color="blue">agreement</font>, <font color="blue">Roche     </font>may  commence  legal  action  for damages and/or seek to terminate our     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If Roche does not <font color="blue">manufacture</font>, distribute, price or sell <font color="blue">CellCept </font>at levels     <font color="blue">which <font color="blue">generate sufficient revenue</font></font> for us to operate, we may have to limit or     cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We do not own or operate any <font color="blue">manufacturing</font> or <font color="blue">distribution</font> facilities</td>
    </tr>
    <tr>
      <td>Roche, not Aspreva, controls the <font color="blue">manufacture</font> of <font color="blue">CellCept </font>and we have no     <font color="blue">alternative</font>  supplier</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">adequate supplies</font> of     <font color="blue">CellCept </font> from Roche for our <font color="blue"><font color="blue">clinical trial</font>s</font>, they could be delayed or     prevented</td>
    </tr>
    <tr>
      <td>In addition, if there is a shortage <font color="blue">of CellCept</font>, Roche may decide     to  allocate  available  supplies of <font color="blue">CellCept </font>to purchasers for use in     transplant <font color="blue"><font color="blue">indication</font>s</font> and not autoimmune or other <font color="blue"><font color="blue">indication</font>s</font>, thereby     reducing our revenues</td>
    </tr>
    <tr>
      <td>Roche is <font color="blue">solely responsible</font> for <font color="blue">distributing</font> and     selling  CellCept,  and setting the price, including all <font color="blue">discounts</font> and     rebates, <font color="blue">of CellCept</font></td>
    </tr>
    <tr>
      <td>Rocheapstas <font color="blue">control over</font> the <font color="blue">manufacture</font>, <font color="blue">distribution</font>, pricing and sale of     <font color="blue">CellCept </font><font color="blue">exposes us</font> to a number of risks which are outside our control     including:         •     Roche may fail to <font color="blue">comply with</font> FDA-mandated current good <font color="blue">manufacturing</font>     practices or similar <font color="blue">regulations</font> in other <font color="blue"><font color="blue">jurisdiction</font>s</font> resulting in     <font color="blue">mandated production halts</font> or limitations;       •     Roche may experience <font color="blue">manufacturing</font> quality or <font color="blue">control issues which halt</font> or     limit <font color="blue">CellCept </font>production;       •     a <font color="blue">manufacturing</font> plant may be closed as a result of a <font color="blue">natural disaster</font> or     work stoppage;                                                                               •     Roche may experience short or long-term supply problems, or problems     <font color="blue">distributing</font> CellCept, including <font color="blue"><font color="blue">difficult</font>ies importing</font> or exporting     supplies or products;                                                                               •     Roche may decrease its efforts to market and promote <font color="blue">CellCept </font>for the     transplant <font color="blue"><font color="blue">indication</font>s</font> thus lowering the <font color="blue">visibility</font> of <font color="blue">CellCept </font>in the     market; and       •     Roche may set a low price for <font color="blue">CellCept </font>or give <font color="blue">discounts</font> or rebates that     <font color="blue"><font color="blue">effective</font>ly</font> lower the price <font color="blue">of CellCept</font>, which in <font color="blue">either case could reduce</font>     our revenues</td>
    </tr>
    <tr>
      <td>However, we may in the <font color="blue">future outsource</font> the <font color="blue">manufacturing</font> of <font color="blue">CellCept </font>for     our <font color="blue"><font color="blue">clinical trial</font>s</font> to <font color="blue">third parties</font> other than Roche, subject to approval     from <font color="blue">Roche and <font color="blue">the FDA     </font>  </font>19       _________________________________________________________________         The expiration of Rocheapstas <font color="blue">patents covering</font> <font color="blue">CellCept </font>may reduce our revenue     <font color="blue">as <font color="blue"><font color="blue">competitor</font>s</font> may seek</font> to <font color="blue">sell generic versions</font> <font color="blue">of CellCept</font></td>
    </tr>
    <tr>
      <td>Roche owns the <font color="blue">patents covering</font> the <font color="blue">composition</font> of matter <font color="blue">of CellCept</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">United States</font> </font><font color="blue">patent covering</font> <font color="blue">CellCept </font>expires in May 2009</td>
    </tr>
    <tr>
      <td><font color="blue">Counterparts </font>of     this patent expire in most European countries in late 2010 or early 2011,     but in some instances expire as early as 2007</td>
    </tr>
    <tr>
      <td>Roche <font color="blue">patents covering</font> the     process for <font color="blue">manufacture</font> of <font color="blue">CellCept </font>expire in the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>in July     </font>2012, and in most other countries in July 2013</td>
    </tr>
    <tr>
      <td><font color="blue">We and Roche </font>expect that     <font color="blue">following expiration</font> of all these patents <font color="blue"><font color="blue">competitor</font>s</font> may <font color="blue">manufacture</font> and     <font color="blue">sell generic versions</font> <font color="blue">of CellCept</font>, at a lower price, which would reduce     CellCeptapstas revenues</td>
    </tr>
    <tr>
      <td>In certain <font color="blue"><font color="blue">jurisdiction</font>s</font>, including most <font color="blue"><font color="blue">Canadian </font>    </font>provinces, <font color="blue">legislation</font> mandates generic substitution for brand <font color="blue">name drugs</font></td>
    </tr>
    <tr>
      <td>If  <font color="blue"><font color="blue">competitor</font>s</font>  devise a means to <font color="blue">manufacture</font> <font color="blue">CellCept </font>which does not     infringe Rocheapstas <font color="blue">patents covering</font> the process for <font color="blue">manufacture</font>, <font color="blue"><font color="blue">competitor</font>s</font>     may  seek  to <font color="blue">sell generic versions</font> of <font color="blue">CellCept </font><font color="blue">upon expiration</font> of the     <font color="blue">composition</font> of matter patents, which occurs in some <font color="blue">countries as early as</font>     2007</td>
    </tr>
    <tr>
      <td>If we obtain an <font color="blue">orphan drug <font color="blue">designation</font></font> and FDA approval of <font color="blue">CellCept </font>for an     <font color="blue">indication</font>, we would be entitled to <font color="blue">seven years</font> of <font color="blue">marketing exclusivity</font> for     that orphan drug <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2006, we were <font color="blue">granted orphan drug</font>     <font color="blue">designation</font>  for  CellCept’s  use  in <font color="blue">myasthenia gravis</font></td>
    </tr>
    <tr>
      <td>However, if a     <font color="blue">competitor</font> obtained approval of a generic form of <font color="blue">CellCept </font>for another     <font color="blue">indication</font>, such as transplant use, physicians would not be <font color="blue">prevented from</font>     prescribing the <font color="blue">generic drug</font> for the orphan <font color="blue">indication</font> during the period of     <font color="blue">marketing exclusivity</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">prescribing practices could <font color="blue">adversely affect</font></font> the     sales of <font color="blue">CellCept </font>for the orphan <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur <font color="blue"><font color="blue">significant</font> <font color="blue">liability</font></font></font> if it is determined that we are promoting     the  &amp;quote off-label &amp;quote  use of drugs or are <font color="blue">otherwise found</font> in violation of federal     and state <font color="blue">regulations</font> in the <font color="blue"><font color="blue">United States</font> </font>or elsewhere</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font><font color="blue">may prescribe <font color="blue">drug products</font></font> for uses that are not described in     the productapstas labelling and that <font color="blue">differ from</font> those <font color="blue">approved by</font> the FDA or     other applicable <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>Such off-label uses are <font color="blue">common across</font>     <font color="blue">medical specialities</font></td>
    </tr>
    <tr>
      <td>We are aware that some physicians are prescribing     <font color="blue">CellCept </font>for the treatment of certain <font color="blue">autoimmune diseases</font>, although neither     we nor Roche are permitted to promote <font color="blue">CellCept </font>for the treatment of any     <font color="blue">autoimmune diseases</font>, and the FDA and other <font color="blue">regulatory</font> agencies have not     approved the use of <font color="blue">CellCept </font>for any autoimmune <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Although the     FDA and other <font color="blue">regulatory</font> agencies do not regulate a physicianapstas choice of     <font color="blue">treatments</font>, the FDA and other <font color="blue">regulatory</font> agencies do <font color="blue">restrict <font color="blue">communications</font></font>     on  the  subject of off-label use</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>may not <font color="blue">promote drugs</font> for     off-label uses</td>
    </tr>
    <tr>
      <td>Accordingly, prior to approval of any autoimmune <font color="blue"><font color="blue">indication</font>s</font>     for CellCept, we may not promote <font color="blue">CellCept </font>for such <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA and     other <font color="blue">regulatory</font> agencies actively enforce <font color="blue">regulations</font> prohibiting promotion     of  off-label  uses  and the promotion of products for <font color="blue">which marketing</font>     clearance has not been obtained</td>
    </tr>
    <tr>
      <td>A company that is found to have <font color="blue">improperly</font>     promoted off-label uses may be subject to <font color="blue"><font color="blue">significant</font> <font color="blue">liability</font></font>, including     civil and <font color="blue"><font color="blue">administrative</font> remedies as well as criminal sanctions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>the <font color="blue">regulatory</font> <font color="blue"><font color="blue">restrictions</font> on</font> off-label promotion, <font color="blue">the FDA     </font>and other <font color="blue">regulatory</font> <font color="blue">authorities</font> allow companies to engage in truthful,     non-misleading, and non-promotional speech concerning their products</td>
    </tr>
    <tr>
      <td>We     engage in medical education <font color="blue">activities</font> and communicate <font color="blue">with investigators</font>     and <font color="blue">potential investigators</font> regarding our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Although we     believe that all of our <font color="blue">communications</font> regarding <font color="blue">CellCept </font>are in compliance     with the relevant <font color="blue">regulatory</font> <font color="blue">requirements</font>, the FDA or another <font color="blue">regulatory</font>     <font color="blue">authority may disagree</font>, and we may be subject to <font color="blue"><font color="blue">significant</font> <font color="blue">liability</font></font>,     including civil and <font color="blue"><font color="blue">administrative</font> remedies as well as criminal sanctions</font></td>
    </tr>
    <tr>
      <td>We and our <font color="blue"><font color="blue">collaborator</font>s</font> are also subject <font color="blue">to the US </font>federal False Claims     Act and US federal Anti-Kickback law</td>
    </tr>
    <tr>
      <td>We have developed a <font color="blue">comprehensive</font>     <font color="blue">compliance program</font> that seeks to <font color="blue">establish internal controls</font> to <font color="blue">facilitate</font>     adherence to the rules and <font color="blue">program <font color="blue">requirements</font></font> to which we are and will     become subject</td>
    </tr>
    <tr>
      <td>If, however, we are determined to have violated these and     other laws, we <font color="blue">could incur <font color="blue">significant</font> penalties</font> and be subject to criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>Roche might deem any <font color="blue">such de<font color="blue">termination</font> by</font> a <font color="blue"><font color="blue">government</font>al</font>     authority to <font color="blue">constitute</font> a material breach of our <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">management</font>apstas attention could be diverted and our reputation and our ability     to <font color="blue">enter into</font> future <font color="blue"><font color="blue">collaboration</font>s</font> could be damaged</td>
    </tr>
    <tr>
      <td>If <font color="blue">CellCept </font>and any <font color="blue">future products</font> do not <font color="blue">gain meaningful <font color="blue">market acceptance</font></font>     we are not likely to <font color="blue">generate <font color="blue">significant</font> revenues</font> or sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market acceptance</font> for any product that we <font color="blue">commercialize</font> will     <font color="blue">depend on</font> a number of factors, including:         •     <font color="blue">acceptance by physicians</font> and patients of <font color="blue">each product as safe</font> and <font color="blue">effective</font>;       •     <font color="blue">potential advantages over existing</font> or <font color="blue">alternative</font> therapies, including cost;       •     actual or perceived safety of similar classes of products;       •     <font color="blue">relative convenience</font> and ease of <font color="blue">administration</font>;     20       _________________________________________________________________           •     <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and third-party payors;       •     <font color="blue">effective</font>ness of our sales, marketing and <font color="blue">medical education efforts</font>; and       •     scope of the product label <font color="blue">approved by</font> the FDA and other <font color="blue">regulatory</font>     agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Hospitals </font>or physicians may not choose to <font color="blue">administer</font> <font color="blue">CellCept </font>or any future     product to the <font color="blue">entire <font color="blue">intended market</font></font>, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">CellCept </font>and any future     products do not achieve <font color="blue">meaningful acceptance</font> in their <font color="blue">intended market</font>s or     if the <font color="blue">intended market</font> is <font color="blue">smaller than</font> anticipated, we are not likely to     <font color="blue">generate <font color="blue">significant</font> revenues</font> or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Any  failure  or delay in obtaining <font color="blue">additional</font> capital may curtail the     <font color="blue">development</font> or <font color="blue">commercialization</font> of <font color="blue">CellCept </font>or any <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>We expect that our future need for <font color="blue">additional</font> capital will be substantial</td>
    </tr>
    <tr>
      <td>The extent of this need will <font color="blue">depend on</font> many factors, some of which are     beyond our control, including:         •     our ability to develop and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">CellCept </font>and any     <font color="blue">future products</font> in our targeted <font color="blue"><font color="blue">indication</font>s</font>;       •     our ability to <font color="blue">establish marketing</font> and <font color="blue">sales <font color="blue">capabilities</font></font> and the costs of     launching <font color="blue">CellCept </font>and any <font color="blue">future products</font> for our targeted <font color="blue"><font color="blue">indication</font>s</font>;       •     the extent of <font color="blue">costs associated with protecting</font> and expanding our patent and     other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>;       •     <font color="blue">market acceptance</font> of <font color="blue">CellCept </font>and any <font color="blue">future products</font> for our targeted     <font color="blue"><font color="blue">indication</font>s</font>;       •     <font color="blue">future payments</font>, if any, we receive or make <font color="blue">under existing</font> or future     <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font>;       •     the timing of <font color="blue"><font color="blue">regulatory</font> approval</font>s needed to <font color="blue">market products</font> for our     targeted <font color="blue"><font color="blue">indication</font>s</font>;       •     the need to acquire licenses for <font color="blue">new products</font> or compounds; and       •     <font color="blue"><font color="blue">compliance with</font> rules</font> and <font color="blue">regulations</font> implemented by the <font color="blue">US Securities </font>and     Exchange Commission, <font color="blue">Canadian </font>provincial securities <font color="blue">regulatory</font> <font color="blue">authorities</font>,     the <font color="blue">NASDAQ National Market </font>and the Toronto Stock Exchange</td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">no committed sources</font> of <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>Funds may not be     available to us in the future on favorable terms, if at all, and we may be     required  to  delay,  reduce  the  scope of, or <font color="blue">eliminate research</font> and     <font color="blue">development</font>  efforts  or  <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">CellCept </font>or other future     products</td>
    </tr>
    <tr>
      <td>We may also be forced to curtail or <font color="blue">restructure</font> our <font color="blue">operations</font>,     obtain  funds  by  entering  into  <font color="blue">arrangements</font>  with <font color="blue"><font color="blue">collaborator</font>s</font> on     <font color="blue">unattractive</font>  terms  or  <font color="blue">relinquish</font>  rights to <font color="blue">technologies</font> or product     <font color="blue">candidates</font> that we would not otherwise <font color="blue">relinquish</font> in order to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are not successful in establishing <font color="blue">additional</font> <font color="blue"><font color="blue">collaboration</font>s</font> we will     not be able to grow our business</td>
    </tr>
    <tr>
      <td>Our long-term <font color="blue">success depends upon</font> our ability to identify drugs and drug     <font color="blue">candidates</font> with <font color="blue">significant</font> potential and to acquire the rights for those     <font color="blue"><font color="blue">indication</font>s</font> from multiple <font color="blue"><font color="blue">collaborator</font>s</font>, thus creating <font color="blue">multiple sources</font> of     revenue</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font> from</font> other companies for <font color="blue">collaborative</font>     <font color="blue">arrangements</font> with <font color="blue">pharmaceutical</font> and <font color="blue"><font color="blue">bio<font color="blue">pharmaceutical</font></font> companies</font>, and there     are <font color="blue">no barriers prohibiting</font> other <font color="blue">companies from adopting</font> our business     model</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>and <font color="blue"><font color="blue">bio<font color="blue">pharmaceutical</font></font> companies</font> may also decide to     pursue new <font color="blue"><font color="blue">indication</font>s</font> for their products <font color="blue">themselves</font>, rather than <font color="blue">enter into</font>     <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font> to develop new <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, accurate     <font color="blue">sales tracking may</font> be <font color="blue">difficult</font> or impossible under future <font color="blue"><font color="blue">collaboration</font>s</font>     <font color="blue">which may preclude</font> a <font color="blue">collaboration</font> or lead to <font color="blue">disputes once</font> a <font color="blue">collaboration</font>     has <font color="blue">been established</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently only</font> have one <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>If we are     unable to <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue"><font color="blue">collaboration</font>s</font>, we will continue to be     <font color="blue">dependent upon</font> Roche for <font color="blue">substantially</font> all our revenues, and we will be     limited in our ability to grow our business</td>
    </tr>
    <tr>
      <td>In addition, the fact that we     are <font color="blue">collaborating with</font> Roche, or other potential <font color="blue"><font color="blue">collaborator</font>s</font>, may be     viewed <font color="blue">negatively by</font> other potential <font color="blue"><font color="blue">collaborator</font>s</font>, making <font color="blue">them less likely</font>     to <font color="blue">enter into</font> <font color="blue">arrangements</font> with us</td>
    </tr>
    <tr>
      <td>The terms and <font color="blue">conditions</font> of any future <font color="blue">collaboration</font> <font color="blue">agreement</font>s may be less     favorable than our <font color="blue"><font color="blue">agreement</font> with</font> Roche</td>
    </tr>
    <tr>
      <td>Our  strategy  is  to  seek  <font color="blue"><font color="blue">collaboration</font>s</font>  with  <font color="blue">pharmaceutical</font>  and     <font color="blue"><font color="blue">bio<font color="blue">pharmaceutical</font></font> companies</font> to develop and <font color="blue">commercialize</font> new <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Any new <font color="blue"><font color="blue">collaboration</font>s</font> that we <font color="blue">may secure will likely involve drugs</font> or drug     <font color="blue">candidates</font>, or <font color="blue"><font color="blue">collaborator</font>s</font>, with <font color="blue">characteristics</font> <font color="blue">different</font> from <font color="blue">CellCept </font>    or Roche</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">characteristics</font> may</font> include:         •     costs to <font color="blue">manufacture</font>, distribute and sell;       •     <font color="blue">patent terms</font>;       •     <font color="blue">expenditures by</font> our <font color="blue"><font color="blue">collaborator</font>s</font> on research and <font color="blue">development</font>;       •     size and <font color="blue">difficult</font>y of <font color="blue">development</font> programs for <font color="blue">potential product</font>     <font color="blue"><font color="blue">indication</font>s</font>;       21       _________________________________________________________________           •     <font color="blue">competitive</font> threats; and       •     other <font color="blue">factors relevant</font> to the <font color="blue">development</font> and <font color="blue">commercialization</font> of such     products</td>
    </tr>
    <tr>
      <td>We expect that any new <font color="blue"><font color="blue">collaboration</font>s</font> will be <font color="blue">highly negotiated</font>, and the     above <font color="blue">characteristics</font> all may play a role in the <font color="blue">financial terms</font> of such     <font color="blue"><font color="blue">collaboration</font>s</font>, possibly resulting in any or all of the following:         •     our payment of upfront or <font color="blue">milestone fees</font> for <font color="blue">product rights</font>;       •     <font color="blue">greater <font color="blue">clinical trial</font> expenses</font>;       •     <font color="blue">longer timelines</font> to approval;       •     <font color="blue">lower revenue sharing percentages</font>;       •     shorter <font color="blue">agreement</font> periods; or       •     less than global <font color="blue">product rights</font></td>
    </tr>
    <tr>
      <td>In addition, any new <font color="blue">collaboration</font> <font color="blue">agreement</font> may provide that we only begin     <font color="blue">sharing revenue with</font> our <font color="blue">collaborator</font> after some long period of time after     entering into such <font color="blue">collaboration</font>, or after some <font color="blue">specific action</font> or approval     over which we may have limited control</td>
    </tr>
    <tr>
      <td>If  we  fail  to  establish  sufficient  marketing and <font color="blue">sales promotion</font>     <font color="blue">capabilities</font>, or <font color="blue">enter into</font> successful <font color="blue">arrangements</font> with <font color="blue">third parties</font> to     conduct these <font color="blue">activities</font>, we may be unable to <font color="blue">generate sufficient revenue</font> to     continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Roche is <font color="blue">solely responsible</font> for <font color="blue">distributing</font> and selling CellCept</td>
    </tr>
    <tr>
      <td>If we     obtain  approval of <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font>, or any future     products,  we  intend to market and <font color="blue">promote them through</font> our own sales     promotion  force  in the <font color="blue"><font color="blue">United States</font> </font>and certain other countries</td>
    </tr>
    <tr>
      <td>We     currently  have  no  sales  promotion  <font color="blue">capabilities</font>, limited marketing     <font color="blue">capabilities</font>, limited <font color="blue">infrastructure</font> to support such <font color="blue">activities</font>, and have     limited experience in the <font color="blue">commercialization</font> of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>We     may not be able to attract and retain <font color="blue">qualified marketing</font> or <font color="blue">sales promotion</font>     people or be able to establish an <font color="blue">effective</font> <font color="blue">sales promotion</font> force</td>
    </tr>
    <tr>
      <td>In countries where we do not have a <font color="blue">sales promotion</font> force, we <font color="blue">may establish</font>     <font color="blue">relationship</font>s with <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>However, we may not be able to <font color="blue">enter into</font>     such <font color="blue">arrangements</font> on favorable terms or at all and to the extent that we     <font color="blue">enter into</font> such <font color="blue">arrangements</font>, our revenue will <font color="blue">depend on</font> their efforts,     which may not be successful</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font> are <font color="blue"><font color="blue">successfully</font> brought <font color="blue">against us</font></font>, we will     incur  <font color="blue">significant</font>  <font color="blue">liabilities</font>  and  may  be  required  to  limit the     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our use of <font color="blue">CellCept </font>and other products in <font color="blue"><font color="blue">clinical trial</font>s</font>, and our future     promotion of any products, may expose us to <font color="blue">product <font color="blue">liability</font></font> claims and     associated  <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">global product <font color="blue">clinical trial</font></font>     insurance policy, with aggregate coverage of dlra10dtta0 million, for countries     not  requiring a <font color="blue">local insurance policy</font> (including USA and Canada)</td>
    </tr>
    <tr>
      <td>In     addition, we have policies in <font color="blue">varying amounts</font> for all the other countries in     which we are conducting <font color="blue"><font color="blue">clinical trial</font>s</font>, and which do not <font color="blue">fall within</font> the     scope  of our <font color="blue">global policy</font></td>
    </tr>
    <tr>
      <td>Our insurance coverage may not <font color="blue">protect us</font>     against any or all of the <font color="blue">product <font color="blue">liability</font></font> claims <font color="blue">which could</font> be brought     <font color="blue">against us</font> in the future</td>
    </tr>
    <tr>
      <td>Prior to the <font color="blue">commercialization</font> of <font color="blue">CellCept </font>in     autoimmune <font color="blue"><font color="blue">indication</font>s</font>, we expect to obtain <font color="blue">product <font color="blue">liability</font></font> insurance for     potential claims associated with our promotion <font color="blue">of CellCept</font></td>
    </tr>
    <tr>
      <td>However, we may     not  be  able  to  obtain or maintain <font color="blue">adequate insurance coverage at</font> a     <font color="blue"><font color="blue">commercially</font> reasonable cost</font> or in <font color="blue">sufficient amounts</font> or scope to <font color="blue">protect us</font>     <font color="blue">against potential losses</font></td>
    </tr>
    <tr>
      <td>Roche is obligated to <font color="blue">indemnify us</font> for any product     <font color="blue">liability</font> claims, except if the claims arise due to false or misleading     <font color="blue">promotional activity on</font> our part</td>
    </tr>
    <tr>
      <td>In the event a <font color="blue">product <font color="blue">liability</font></font> claim is     brought <font color="blue">against us</font>, we may be required to pay legal and other expenses to     defend the claim and, if such a claim is successful, damage awards not     covered  by  our  insurance</td>
    </tr>
    <tr>
      <td>We may also be obligated to indemnify our     <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Defending </font>any <font color="blue">product <font color="blue">liability</font></font> claim or claims could require     us to expend <font color="blue">significant</font> financial and managerial resources</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue"><font color="blue">competitor</font>s</font>  are able to develop and <font color="blue">market products</font> that are     <font color="blue">preferred over</font> <font color="blue">CellCept </font>or other product <font color="blue">candidates</font> that we may develop, we     may not be able to <font color="blue">generate sufficient revenue</font>s to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  not  be  able  to  contend <font color="blue">successfully</font> with <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> industries are highly <font color="blue">competitive</font> and     subject to <font color="blue">significant</font> and <font color="blue">rapid technological</font> change <font color="blue">as researchers learn</font>     more <font color="blue">about diseases</font> and develop new <font color="blue">technologies</font> and <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Our current     and   potential  <font color="blue"><font color="blue">competitor</font>s</font>  <font color="blue">generally</font>  include  major  <font color="blue">multinational</font>     <font color="blue">pharmaceutical</font> companies, <font color="blue">bio<font color="blue">pharmaceutical</font></font> firms, specialty <font color="blue">pharmaceutical</font>     companies, universities and other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>In  the  transplant market, <font color="blue">CellCept </font><font color="blue">currently competes with</font> Novartis &amp;apos      product, Myfortic</td>
    </tr>
    <tr>
      <td>If <font color="blue">CellCept </font>is approved for any autoimmune <font color="blue"><font color="blue">indication</font>s</font>,     Novartis may choose to also pursue <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue"><font color="blue">regulatory</font> approval</font>     for the same <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>If approved, <font color="blue">CellCept </font><font color="blue">will also compete with</font>     <font color="blue">immunosuppressants</font>,  such  as steroids and <font color="blue"><font color="blue">cytotoxic agent</font>s</font>, including     cyclophosphamide, cyclosporine and <font color="blue">azathioprine</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">cytotoxic agent</font> is an     anti-cancer substance that acts by killing or preventing the division of     cells</td>
    </tr>
    <tr>
      <td>In addition, we are aware of <font color="blue">several companies</font> that have products in     <font color="blue">development</font> or on the market that may be <font color="blue">competitive</font> with <font color="blue">CellCept </font>in lupus     nephritis, <font color="blue">myasthenia gravis</font> and pemphigus vulgaris</td>
    </tr>
    <tr>
      <td>Some of the companies     have commenced <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">products targeting</font> the <font color="blue">same markets</font> and     <font color="blue"><font color="blue">indication</font>s</font> that we are <font color="blue">addressing</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________         The existence of these products, other products or <font color="blue">treatments</font> of which we     are not aware, or products or <font color="blue">treatments</font> that may be developed in the future     may  reduce  the  <font color="blue">marketability</font>  of  <font color="blue">CellCept </font>and any <font color="blue">future products</font>,     <font color="blue">particularly</font> to the <font color="blue">extent such products</font>:         •     are more <font color="blue">effective</font>;       •     have fewer or <font color="blue">less severe adverse</font> side effects;       •     have <font color="blue">better patient compliance</font>;       •     receive <font color="blue">better <font color="blue">reimbursement</font> terms</font>;       •     are <font color="blue">accepted by</font> more physicians;       •     are more adaptable to <font color="blue">various modes</font> of dosing;       •     have better <font color="blue">distribution</font> channels;       •     are easier to <font color="blue">administer</font>; or       •     are <font color="blue">less expensive</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">competitor</font>s</font>, <font color="blue">either alone</font> or <font color="blue">together with</font> their <font color="blue"><font color="blue">collaborator</font>s</font>,     have  <font color="blue">substantially</font>  greater  financial resources and larger research,     <font color="blue">development</font> and <font color="blue">regulatory</font> staffs than we do</td>
    </tr>
    <tr>
      <td>In addition, many of our     <font color="blue"><font color="blue">competitor</font>s</font>,  either  alone or <font color="blue">together with</font> their <font color="blue"><font color="blue">collaborator</font>s</font>, have     <font color="blue">significant</font>ly greater experience than we do in <font color="blue">discovering</font>, developing,     <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>mergers and <font color="blue"><font color="blue">acquisition</font>s</font> in     the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries may result in even more     resources being <font color="blue">concentrated</font> in our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">effective</font>ly</font> manage our expected <font color="blue">future growth</font>, we may be     unable to develop or <font color="blue">commercialize</font> <font color="blue">CellCept </font>or any other <font color="blue">product candidate</font>     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>In 2005, we increased our number of employees by 53 and, as of <font color="blue">December </font>31,     2005,  we  had 106 employees</td>
    </tr>
    <tr>
      <td>In order to continue the <font color="blue">development</font> and     potential <font color="blue">commercialization</font> of <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font> and enter     into new <font color="blue"><font color="blue">collaboration</font>s</font> we will need to expand our <font color="blue">clinical <font color="blue">development</font></font>,     <font color="blue">regulatory</font>, marketing and <font color="blue">sales promotion</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We currently have     <font color="blue">operations</font>  in  Canada,  the  United  States,  the United Kingdom, and     Switzerland</td>
    </tr>
    <tr>
      <td>Our ability to manage our global <font color="blue">operations</font> and expected growth     will  require us to continue to improve our operational, financial and     <font color="blue">management</font> controls, reporting systems and procedures</td>
    </tr>
    <tr>
      <td>We may not be able to     make <font color="blue">such improvements</font> in an <font color="blue">efficient</font> or <font color="blue">timely manner</font> and <font color="blue">may discover</font>     <font color="blue">deficiencies</font> in <font color="blue">existing systems</font> and controls</td>
    </tr>
    <tr>
      <td>Our ability to develop and     <font color="blue">commercialize</font> products for new <font color="blue"><font color="blue">indication</font>s</font> and compete <font color="blue"><font color="blue">effective</font>ly</font>, and our     <font color="blue">future financial performance will depend</font>, in part, on our ability to manage     any <font color="blue">future growth</font> <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our <font color="blue"><font color="blue">executive officer</font>s</font>, and if we are not able to retain them     or recruit <font color="blue">additional</font> qualified personnel, we may be unable to <font color="blue">successfully</font>     develop or <font color="blue">commercialize</font> CellCept</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success depends upon</font> the <font color="blue">continued contributions</font> of our executive     officers and scientific and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent on</font>     Richard  M  Glickman,  our Chief Executive Officer, Noel F Hall, our     President, Bruce Cousins, our Chief Financial Officer, and Reinhard WA     Baildon, our Executive Vice President, Clinical and Regulatory Affairs</td>
    </tr>
    <tr>
      <td>Due     to the <font color="blue">specialized knowledge</font> that each of our <font color="blue"><font color="blue">executive officer</font>s</font> possess     with respect to <font color="blue">CellCept </font>and our <font color="blue">operations</font>, the loss of service of any of     our <font color="blue"><font color="blue">executive officer</font>s</font> could delay or prevent the <font color="blue">successful <font color="blue">completion</font></font> of     the <font color="blue"><font color="blue">clinical trial</font>s</font> necessary for the <font color="blue">commercialization</font> of <font color="blue">CellCept </font>for     lupus nephritis, <font color="blue">myasthenia gravis</font> or pemphigus vulgaris and could harm our     <font color="blue">relationship</font> with Roche</td>
    </tr>
    <tr>
      <td>We carry <font color="blue"><font color="blue">key man life insurance</font> coverage</font> of dlra1dtta2     million for each of <font color="blue">Richard M Glickman and Noel F Hall</font></td>
    </tr>
    <tr>
      <td>We do not carry     <font color="blue">key man life insurance</font> for any of our other <font color="blue"><font color="blue">executive officer</font>s</font></td>
    </tr>
    <tr>
      <td>We have employment <font color="blue">agreement</font>s with each of our <font color="blue"><font color="blue">executive officer</font>s</font>; however,     <font color="blue">each may terminate</font> their <font color="blue">employment upon</font> notice and without cause or good     reason</td>
    </tr>
    <tr>
      <td>We currently are not aware that any <font color="blue">executive officer</font> is planning to     leave or retire</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success also depends</font> in part on our ability to attract and retain highly     qualified scientific, commercial and <font color="blue"><font color="blue">administrative</font> personnel</font></td>
    </tr>
    <tr>
      <td>In order to     pursue our product <font color="blue">development</font> and <font color="blue">commercialization</font> strategies, we will     need to attract and hire <font color="blue">additional</font> personnel with experience in a number of     <font color="blue">disciplines</font>, including clinical testing, <font color="blue">government</font> regulation, sales and     marketing, drug <font color="blue">reimbursement</font> and information systems</td>
    </tr>
    <tr>
      <td>There is intense     <font color="blue">competition</font> for personnel in the fields in which we operate</td>
    </tr>
    <tr>
      <td>We have not     experienced <font color="blue">difficult</font>y to date in attracting and retaining the personnel we     require</td>
    </tr>
    <tr>
      <td>If, however, we are unable to continue to <font color="blue">attract new employees</font> and     retain <font color="blue">existing employees</font>, we may be unable to continue our <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________         We may incur losses associated with currency <font color="blue">fluctuations</font> and may not be     able to <font color="blue"><font color="blue">effective</font>ly</font> hedge our exposure</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are in many <font color="blue">instances conducted</font> in currencies other than the     US dollar and <font color="blue">fluctuations</font> in the value of <font color="blue">currencies relative</font> <font color="blue">to the US </font>    <font color="blue">dollar could</font> cause us to <font color="blue">incur currency exchange losses</font></td>
    </tr>
    <tr>
      <td>All <font color="blue"><font color="blue">amounts paid</font> by</font>     Roche to us will be <font color="blue">in Swiss Francs</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">currently conduct</font> some     <font color="blue">operations</font> and incur a portion of our expenses in <font color="blue">Canadian </font>dollars, pounds     sterling and other <font color="blue">foreign currencies</font></td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">implemented currency</font>     hedging  <font color="blue">techniques</font>  during 2005  to  mitigate  the impact of currency     <font color="blue">fluctuations</font> on our financial results, these <font color="blue">techniques</font> do not eliminate the     effects of currency <font color="blue">fluctuations</font> with respect to anticipated revenues or     <font color="blue">cash flows</font>, and, as they are short term in nature, do not <font color="blue">protect us</font> from     <font color="blue">prolonged period</font>s of currency <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue">CellCept </font> net sales are <font color="blue">denominated</font> in <font color="blue">multiple currencies</font> and will be     converted to <font color="blue">Swiss Francs </font>by Roche for the purpose of <font color="blue">calculating amounts</font> to     be paid to us</td>
    </tr>
    <tr>
      <td>To the extent <font color="blue">the Swiss Franc </font>increases in <font color="blue">value relative</font> to     these other currencies, the <font color="blue">total aggregate value</font> <font color="blue">of CellCept</font>apstas net sales     will  decrease  and the amount, if any, that we are entitled to may be     reduced</td>
    </tr>
    <tr>
      <td>Risks Related to Regulatory Matters       We will not be able to <font color="blue">commercialize</font> our product <font color="blue">candidates</font> if our clinical     trials do not <font color="blue"><font color="blue">demonstrate</font> safety</font> and efficacy in humans</td>
    </tr>
    <tr>
      <td>We  are  currently  not  authorized  to market <font color="blue">CellCept </font>for autoimmune     <font color="blue"><font color="blue">indication</font>s</font> in any <font color="blue">jurisdiction</font>, and we may never be authorized to market     <font color="blue">CellCept </font>  for   any   autoimmune   <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font>  and     <font color="blue">commercialization</font> of <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font>, and any future     products, are subject to extensive and <font color="blue">rigorous <font color="blue">regulation by</font></font> the US     federal <font color="blue">government</font>, <font color="blue">principally</font> the FDA, other federal, state and local     agencies,  and  <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> elsewhere</td>
    </tr>
    <tr>
      <td>Prior to marketing     <font color="blue">CellCept </font>for any autoimmune <font color="blue">indication</font>, we must conduct, at our own expense,     extensive <font color="blue"><font color="blue">clinical trial</font>s</font> to <font color="blue"><font color="blue">demonstrate</font> with</font> substantial evidence to the     <font color="blue">satisfaction</font> of the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font> that <font color="blue">CellCept </font>is     safe and <font color="blue">effective</font> for the <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>We have no prior experience as a     company in conducting <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>studies and clinical     trials are expensive, can take many years and have <font color="blue">uncertain outcomes</font></td>
    </tr>
    <tr>
      <td>In     addition,  the <font color="blue"><font color="blue">regulatory</font> approval</font> procedures vary among countries and     <font color="blue">additional</font>  <font color="blue">testing may</font> be required in some <font color="blue"><font color="blue">jurisdiction</font>s</font></td>
    </tr>
    <tr>
      <td>It may take     <font color="blue">several years</font> to complete the requisite <font color="blue"><font color="blue">clinical trial</font>s</font>, and a product     <font color="blue">candidate may fail</font> any stage of testing</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>and risks associated     with  clinical  trials may result in our failure to receive <font color="blue">regulatory</font>     approval to market <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font> or our <font color="blue">inability</font> to     <font color="blue">commercialize</font>  any <font color="blue">future products</font> for new <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA, other     <font color="blue">regulatory</font> <font color="blue">authorities</font>, our <font color="blue"><font color="blue">collaborator</font>s</font>, or we may suspend or terminate     <font color="blue"><font color="blue">clinical trial</font>s</font> at any time</td>
    </tr>
    <tr>
      <td>The commencement and <font color="blue">completion</font> of our clinical     <font color="blue">trials could</font> be delayed or <font color="blue">prevented by several factors</font>, including:         •     delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s to commence or continue a study;       •     delays in identifying and reaching <font color="blue">agreement</font> on acceptable terms with     <font color="blue">prospective <font color="blue">clinical trial</font> sites</font>;       •     insufficient quantities of the study drug;       •     <font color="blue">slower than</font> expected rates of <font color="blue">patient <font color="blue">recruitment</font></font> and <font color="blue">enrollment</font> or the     <font color="blue">inability</font> to reach full <font color="blue">enrollment</font>;       •     <font color="blue">inconclusive</font> or <font color="blue">negative interim</font> results during <font color="blue"><font color="blue">clinical trial</font>s</font>, including     lack of <font color="blue">effective</font>ness or <font color="blue">unforeseen safety issues</font>;       •     death of, or <font color="blue">serious adverse effects</font> experienced by, one or more patients     during a <font color="blue"><font color="blue">clinical trial</font> even</font> if the reasons are not related to the study     drug, including the <font color="blue">advanced stage</font> of the patientapstas disease or medical     condition;       •     <font color="blue">uncertain dosing issues</font>;       •     <font color="blue">inability</font> to <font color="blue">monitor patients <font color="blue">adequately</font> during</font> and after treatment;       •     <font color="blue">inability</font> or <font color="blue">unwillingness</font> of <font color="blue">contract laboratories</font> to follow good     <font color="blue">laboratory practices</font>;       •     <font color="blue">inability</font> or <font color="blue">unwillingness</font> of <font color="blue">clinical investigators</font> to follow our clinical     protocols or good <font color="blue">clinical practices</font> <font color="blue">generally</font>; and       •     <font color="blue">inability</font> or <font color="blue">unwillingness</font> of other <font color="blue">third parties</font> to perform <font color="blue">data collection</font>     and analysis in a timely or accurate manner</td>
    </tr>
    <tr>
      <td>Delays or failures in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s may:         •     delay or prevent the <font color="blue">commercialization</font> of any product that we develop for     new <font color="blue"><font color="blue">indication</font>s</font>;     24       _________________________________________________________________           •     diminish any <font color="blue">competitive</font> advantages;       •     reduce or <font color="blue">eliminate revenue from</font> the sale of <font color="blue">CellCept </font>and any future     products; and       •     <font color="blue">adversely affect</font> our ability to attract new <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>The results of early <font color="blue"><font color="blue">clinical trial</font>s</font> do not <font color="blue">necessarily predict</font> the results     of later <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We are aware that Roche <font color="blue">conducted three phase</font> III clinical     trials for <font color="blue">CellCept </font>in the treatment of <font color="blue">rheumatoid arthritis which</font> did not     <font color="blue"><font color="blue">demonstrate</font> efficacy</font></td>
    </tr>
    <tr>
      <td>Even if we believe the <font color="blue">data collected from clinical</font>     trials of drugs are promising, such data may not be sufficient to support     <font color="blue">approval by</font> the FDA or any other <font color="blue">regulatory</font> authority</td>
    </tr>
    <tr>
      <td>The FDA or other     <font color="blue">regulatory</font> <font color="blue">authorities</font> could also interpret our data <font color="blue">different</font>ly, which     could delay, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We expect to rely in part on the results of <font color="blue">CellCept </font><font color="blue"><font color="blue">clinical trial</font>s</font> that     were <font color="blue">previously</font> performed by or on behalf of Roche and on <font color="blue"><font color="blue">clinical trial</font>s</font>     that  were  <font color="blue">previously</font> performed or are being performed by third-party     physicians</td>
    </tr>
    <tr>
      <td>These trial results may not be predictive of the results of the     <font color="blue"><font color="blue">clinical trial</font>s</font> that we plan to conduct for the purposes of our targeted     <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, the results of prior <font color="blue"><font color="blue">clinical trial</font>s</font> may not be     acceptable to the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> because the data may     be incomplete, outdated or not otherwise acceptable for inclusion in our     <font color="blue">submissions</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">CellCept </font>in autoimmune <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Even  if  <font color="blue">CellCept </font>or any future <font color="blue">product candidate</font> receives <font color="blue">regulatory</font>     approval, we and our <font color="blue"><font color="blue">collaborator</font>s</font> may still face <font color="blue">development</font> and <font color="blue">regulatory</font>     <font color="blue">difficult</font>ies that may delay or <font color="blue">impair <font color="blue">future sales</font></font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue"><font color="blue">collaborator</font>s</font> obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">CellCept </font>for any     of our targeted <font color="blue"><font color="blue">indication</font>s</font>, or any other product, we and our <font color="blue"><font color="blue">collaborator</font>s</font>     will  continue to be subject to extensive <font color="blue">regulation by</font> the FDA, other     federal <font color="blue">authorities</font>, certain state agencies and <font color="blue">regulatory</font> <font color="blue">authorities</font>     elsewhere</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> will impact many aspects of our <font color="blue">operations</font> and     the drug <font color="blue">manufacture</font>rapstas <font color="blue">operations</font> including <font color="blue">manufacture</font>, record keeping,     quality control, adverse event reporting, storage, labelling, advertising,     promotion, sale and <font color="blue">distribution</font>, export and personnel</td>
    </tr>
    <tr>
      <td>The FDA and state     agencies may conduct periodic <font color="blue">inspections</font> to assess <font color="blue">compliance with</font> these     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We, <font color="blue">together with</font> our <font color="blue"><font color="blue">collaborator</font>s</font>, will be required to     conduct post-marketing surveillance of the product</td>
    </tr>
    <tr>
      <td>We also may be required     to conduct post-marketing studies</td>
    </tr>
    <tr>
      <td>Our or our <font color="blue"><font color="blue">collaborator</font>s</font> &amp;apos  failure to     <font color="blue">comply with</font> applicable FDA and other <font color="blue">regulatory</font> <font color="blue">requirements</font>, or the later     <font color="blue">discovery</font>  of  <font color="blue">previously</font> unknown problems, may result in <font color="blue">restrictions</font>     including:         •     delays in <font color="blue">commercialization</font>;       •     <font color="blue">refusal by</font> the FDA or other similar <font color="blue">regulatory</font> agencies to <font color="blue">review pending</font>     <font color="blue"><font color="blue">application</font>s</font> or <font color="blue">supplements</font> to approved <font color="blue"><font color="blue">application</font>s</font>;       •     <font color="blue">product recalls</font> or seizures;       •     <font color="blue">warning letters</font>;       •     suspension of <font color="blue">manufacturing</font>;       •     <font color="blue">withdrawals</font> of <font color="blue">previously</font> approved marketing <font color="blue"><font color="blue">application</font>s</font>;       •     fines and other <font color="blue">civil penalties</font>;       •     injunctions, suspensions or <font color="blue">revocations</font> of <font color="blue">marketing licenses</font>;       •     refusals to <font color="blue">permit products</font> to be imported to or <font color="blue">exported from</font> the United     States; and       •     criminal <font color="blue">prosecution</font>s</td>
    </tr>
    <tr>
      <td>Post-approval  marketing  laws  and <font color="blue">regulations</font> in other <font color="blue"><font color="blue">jurisdiction</font>s</font>     <font color="blue">generally</font> provide for the <font color="blue">same types</font> of sanctions that may be imposed in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We may experience delays in patient <font color="blue">enrollment</font>, which would delay <font color="blue">regulatory</font>     approval of <font color="blue">CellCept </font>in autoimmune <font color="blue"><font color="blue">indication</font>s</font> and possibly reduce our     revenues</td>
    </tr>
    <tr>
      <td>Our ability to obtain, and the timing of, <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">CellCept </font>    in any autoimmune <font color="blue">indication</font> depends in part on our ability to <font color="blue">successfully</font>     complete <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">CellCept </font>in that autoimmune <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>The     ability to complete <font color="blue"><font color="blue">clinical trial</font>s</font> depends, in part, on the rate of patient     <font color="blue">enrollment</font> and patient retention, which is a function of many factors, some     of which are beyond our control</td>
    </tr>
    <tr>
      <td>In particular, because some of our clinical     <font color="blue">trials will</font> be blinded so that some patients receive <font color="blue">CellCept </font>and others     receive another drug or a placebo, and because <font color="blue">CellCept </font>is marketed for     transplant <font color="blue"><font color="blue">indication</font>s</font> and prescribed by physicians, patients may not want     to <font color="blue">participate</font> in a <font color="blue">clinical trial</font> in which they could receive a placebo or     drug other than CellCept</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       If  third-party  clinical  <font color="blue">research <font color="blue">organizations</font></font> do not perform in an     acceptable  and <font color="blue">timely manner</font>, our <font color="blue"><font color="blue">clinical trial</font>s</font> could be delayed or     <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>We have limited experience as a company in conducting and <font color="blue">managing clinical</font>     trials,  and  rely  on  third  parties,  including  contract  research     <font color="blue">organizations</font>, outside consultants and <font color="blue">principal investigators</font> to <font color="blue">assist us</font>     in managing, monitoring and conducting our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We rely on these     parties to assist in the <font color="blue">recruitment</font> of sites for <font color="blue">participation</font> in clinical     trials, to maintain positive <font color="blue">relations with</font> the <font color="blue">clinical sites</font> and to ensure     that these <font color="blue">sites conduct</font> the trials in <font color="blue">compliance with</font> the protocol and our     <font color="blue">instructions</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> fail to perform <font color="blue">satisfactorily</font> or do     not <font color="blue">adequately</font> fulfill their <font color="blue">obligations</font> to us, our <font color="blue"><font color="blue">clinical trial</font>s</font> may be     delayed or <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>The FDA or other <font color="blue">regulatory</font> agencies may inspect     some of our <font color="blue">clinical sites</font> or our third-party vendors &amp;apos  sites, to determine     if  our  <font color="blue"><font color="blue">clinical trial</font>s</font> are being <font color="blue">conducted according</font> to current good     <font color="blue">clinical practices</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or another applicable <font color="blue">regulatory</font> agency     determines  that  our  third-party  vendors are not in <font color="blue">compliance with</font>     applicable <font color="blue">regulations</font>, we may be required to delay, repeat or terminate     such <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Any delay, repetition or <font color="blue">termination</font> of our clinical     trials  could  prevent  or delay the <font color="blue">commercialization</font> of <font color="blue">CellCept </font>for     autoimmune <font color="blue"><font color="blue">indication</font>s</font> and any other future <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and third-party payors fail to <font color="blue">provide coverage</font> and adequate     <font color="blue"><font color="blue">reimbursement</font> rates</font> for our product <font color="blue">candidates</font>, our revenues and potential     for <font color="blue">profitability</font> will be reduced</td>
    </tr>
    <tr>
      <td>In  the  <font color="blue"><font color="blue">United States</font> </font>and elsewhere, our product revenues will depend     <font color="blue">principally</font> upon the <font color="blue"><font color="blue">reimbursement</font> rates</font> established by third-party payors,     including  <font color="blue">government</font>  health <font color="blue">administration</font> <font color="blue">authorities</font>, managed-care     providers,  public  health insurers, private health insurers and other     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>These third-party payors are <font color="blue">increasingly challenging</font> the     price,  and  examining the cost <font color="blue">effective</font>ness, of <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">significant</font>  <font color="blue">uncertainty</font>  exists  as  to the     <font color="blue">reimbursement</font>  status, if any, of newly <font color="blue">approved drugs</font>, <font color="blue">pharmaceutical</font>     products or product <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We may need to conduct post-marketing     <font color="blue"><font color="blue">clinical trial</font>s</font> in order to <font color="blue">demonstrate</font> the cost-<font color="blue">effective</font>ness of products</td>
    </tr>
    <tr>
      <td>Such <font color="blue">studies may</font> require us to commit a <font color="blue">significant</font> amount of <font color="blue">management</font>     time and financial and other resources</td>
    </tr>
    <tr>
      <td><font color="blue">CellCept </font>is included in <font color="blue">various drug</font>     <font color="blue">compendia as</font> a <font color="blue"><font color="blue">commercially</font> approved drug</font> in <font color="blue">connection with</font> the prevention     of organ rejection and certain third party payors provide <font color="blue">reimbursement</font> for     this use of <font color="blue">CellCept </font>because of <font color="blue">such inclusion</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">CellCept </font>or other     <font color="blue">future products</font> may not be reimbursed or <font color="blue">covered by</font> any of these third-party     payors for our targeted <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>In some countries other than the <font color="blue">United States</font>, <font color="blue">particularly</font> the countries     of  the  European  Union  and  Canada,  the  pricing  of  <font color="blue">prescription</font>     <font color="blue">pharmaceutical</font>s is subject to <font color="blue"><font color="blue">government</font>al</font> control</td>
    </tr>
    <tr>
      <td>In these countries,     obtaining <font color="blue">pricing approval</font> from <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> can take six to     <font color="blue">twelve months</font> or longer after the receipt of <font color="blue">regulatory</font> marketing approval     of a product for an <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>To obtain <font color="blue">reimbursement</font> or <font color="blue">pricing approval</font>     in some countries, we may be required to conduct a <font color="blue">clinical trial</font> that     compares  the cost-<font color="blue">effective</font>ness of a product that is the subject of a     <font color="blue">collaboration</font> with us to other <font color="blue">available therapies</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> of such     products is unavailable or limited in scope or amount or if pricing is set     at unsatisfactory levels our <font color="blue">revenues could</font> be reduced</td>
    </tr>
    <tr>
      <td>Domestic and foreign <font color="blue">government</font>s continue to propose and pass <font color="blue">legislation</font>     designed to reduce the cost of healthcare, including drugs</td>
    </tr>
    <tr>
      <td>In the United     States, there have been, and we expect that <font color="blue"><font color="blue">there will</font> continue</font> to be,     federal and state proposals to implement similar <font color="blue"><font color="blue">government</font>al</font> control</td>
    </tr>
    <tr>
      <td>In     addition, increasing emphasis on managed care in the <font color="blue"><font color="blue">United States</font> </font>will     continue to <font color="blue">put pressure on</font> the pricing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>For     example, the Medicare Prescription Drug Improvement and Modernization Act of     2003 reforms the way Medicare will cover and reimburse for <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">legislation</font> expands Medicare coverage for <font color="blue">drug purchases by</font>     the elderly and has resulted in a new <font color="blue">reimbursement</font> <font color="blue">methodology</font> based on     <font color="blue">average sales prices</font> for <font color="blue">certain drugs</font></td>
    </tr>
    <tr>
      <td>In addition, the new <font color="blue">legislation</font>     <font color="blue">provides authority</font> for limiting the number of <font color="blue">outpatient drugs</font> that will be     covered in any <font color="blue">therapeutic</font> class</td>
    </tr>
    <tr>
      <td>As a result of the new <font color="blue">legislation</font> and the     expansion of <font color="blue">federal coverage</font> of <font color="blue">drug products</font>, we expect that <font color="blue">there will</font> be     <font color="blue">additional</font> pressure to contain and <font color="blue">reduce costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Medicaid </font>program has     <font color="blue">recently been modified</font> and state <font color="blue">healthcare laws</font> and <font color="blue">regulations</font> will soon     be amended to conform to the federal changes</td>
    </tr>
    <tr>
      <td>The new laws and <font color="blue">regulations</font>     will reduce Medicaid <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control initiatives could decrease</font>     the established <font color="blue"><font color="blue">reimbursement</font> rates</font> that we receive for any products in the     future, which would limit our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>and     <font color="blue">regulations</font> <font color="blue">affecting</font> the pricing of <font color="blue">pharmaceutical</font> products, including     CellCept, may change at any time, <font color="blue">which could</font> further limit or eliminate     <font color="blue"><font color="blue">reimbursement</font> rates</font> for <font color="blue">CellCept </font>or other products</td>
    </tr>
    <tr>
      <td>Risks Related to Intellectual Property       We  may  incur <font color="blue">significant</font> expenses or be <font color="blue">prevented from</font> developing or     <font color="blue">commercializing</font>  products  as  a  result  of  an <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">infringement</font> claim</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success depends</font> in part on our ability to operate without     infringing  the patents and other <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Infringement </font><font color="blue">proceedings</font> in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries     are lengthy, costly and time-consuming and their outcome is uncertain</td>
    </tr>
    <tr>
      <td>If we     become  involved  in  any  patent  <font color="blue">litigation</font>,  <font color="blue">interference</font>  or other     <font color="blue">administrative</font>  <font color="blue">proceedings</font>, we will incur substantial expense and the     efforts of our technical and <font color="blue">management</font> personnel will be <font color="blue">significant</font>ly     diverted</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">such <font color="blue">litigation</font></font> or <font color="blue">proceedings</font> we could lose our     <font color="blue">proprietary</font>  position  and be restricted or <font color="blue">prevented from</font> developing,     <font color="blue">manufacturing</font> and selling the affected products, incur <font color="blue">significant</font> damage     awards, including punitive damages, or be required to seek third-party     licenses that may not be available on <font color="blue">commercially</font> acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________         <font color="blue">Although Roche </font>has an extensive <font color="blue">patent estate covering</font> the <font color="blue">composition</font> of     matter, methods of treatment and <font color="blue">manufacture</font> <font color="blue">of CellCept</font>, it is possible     that a <font color="blue">third party may</font> be issued a <font color="blue">patent covering</font> some aspect of <font color="blue">CellCept </font>    or its use</td>
    </tr>
    <tr>
      <td>If this happens, we and Roche may be <font color="blue">restricted from</font> developing     and <font color="blue">commercializing</font> <font color="blue">CellCept </font>for autoimmune <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>If a third party     brings an <font color="blue">infringement</font> claim <font color="blue">against us</font> based solely upon the <font color="blue">development</font> or     promotion of <font color="blue">CellCept </font>in autoimmune <font color="blue"><font color="blue">indication</font>s</font>, Roche has the right under     our <font color="blue">agreement</font> to deduct 50prca of its cost in defending such action, plus any     <font color="blue">amounts paid</font> in settlement or in a <font color="blue">judgment against</font> Roche or Aspreva, from     the <font color="blue">calculation</font> of CeIlCeptapstas <font color="blue">net sales prior</font> to determining our share of     such sales</td>
    </tr>
    <tr>
      <td>Roche is obligated to <font color="blue">indemnify us</font> if the <font color="blue">infringing activity</font>     relates  to  the <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">CellCept </font>in both     transplant and non-transplant <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue"><font color="blue">collaborator</font>s</font> are unable to <font color="blue">adequately</font> protect or enforce our     <font color="blue"><font color="blue">intellectual</font> property</font>, our <font color="blue">competitive</font> position could be impaired</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success depends</font> in part on our ability to:         •     obtain patents or rights to patents and maintain their validity;       •     protect our <font color="blue">trade secrets</font>; and       •     <font color="blue"><font color="blue">effective</font>ly</font> enforce our <font color="blue"><font color="blue">proprietary</font> rights</font> or <font color="blue">patents against infringers</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font> may not result in patents being issued</td>
    </tr>
    <tr>
      <td>As a     result, we may face <font color="blue">unanticipated</font> <font color="blue">competition</font>, or conclude that, without     patent rights, the risk of bringing products to the market is too great</td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue"><font color="blue">collaborator</font>s</font> are issued <font color="blue">patents covering</font> our products we     <font color="blue">cannot predict with certainty whether</font> we or our <font color="blue"><font color="blue">collaborator</font>s</font> will be able     to <font color="blue">ultimately enforce</font> our patents or <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Any patents that we     own or <font color="blue">license may</font> be challenged, invalidated or <font color="blue">circumvented</font> and may not     provide us with protection against <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>We or our <font color="blue"><font color="blue">collaborator</font>s</font> may     be forced to engage in costly and time-consuming <font color="blue">litigation</font> in order to     protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue"><font color="blue">collaborator</font>s</font> may     choose not to enforce or maintain their <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, and we     may be forced to incur substantial <font color="blue">additional</font> costs to maintain or enforce     <font color="blue">such rights</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">rights may</font> not provide us with adequate <font color="blue">proprietary</font>     protection  or <font color="blue">competitive</font> advantages against <font color="blue"><font color="blue">competitor</font>s</font> with similar     products or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The laws of <font color="blue">certain foreign countries</font> do not     protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> to the <font color="blue">same extent as</font> do the laws     of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition to patents, we rely on <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>We <font color="blue">seek protection</font>, in part, <font color="blue">through <font color="blue">confidential</font>ity</font> and non-<font color="blue">disclosure</font>     <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may not <font color="blue">provide meaningful protection</font> of our     <font color="blue">technology</font>  or  adequate  remedies in the event of <font color="blue">unauthorized use</font> or     <font color="blue">disclosure</font> of <font color="blue">confidential</font> and <font color="blue">proprietary</font> information and, in any event,     <font color="blue">others may</font> develop <font color="blue">independently</font>, or obtain access to, the same or similar     information</td>
    </tr>
    <tr>
      <td>Our failure or <font color="blue">inability</font> to protect our <font color="blue">trade secrets</font> and     <font color="blue">proprietary</font> know-how could impair our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Our stock price is volatile and purchasers of our <font color="blue"><font color="blue">common shares</font> could incur</font>     substantial losses</td>
    </tr>
    <tr>
      <td>Since our <font color="blue">initial public offering on</font> March 4,     2005 and through <font color="blue">February </font>15, 2006 our <font color="blue">common shares</font> have traded on the     <font color="blue">NASDAQ National Market </font>between dlra11dtta18 and dlra27dtta90 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font>     in general and the market for <font color="blue">bio<font color="blue">pharmaceutical</font></font> and <font color="blue">bio<font color="blue">technology</font></font> companies     in  particular have experienced <font color="blue">extreme volatility</font> that has often been     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>The price     for our <font color="blue">common shares</font> may be influenced by many factors, including:       •     our ability to develop and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">CellCept </font>and any     <font color="blue">future products</font> in our targeted <font color="blue"><font color="blue">indication</font>s</font>;       •     our ability to <font color="blue">establish marketing</font> and <font color="blue">sales <font color="blue">capabilities</font></font> and the costs of     launching <font color="blue">CellCept </font>and any <font color="blue">future products</font> for our targeted <font color="blue"><font color="blue">indication</font>s</font>;       •     <font color="blue">market acceptance</font> of <font color="blue">CellCept </font>and any <font color="blue">future products</font> for our targeted     <font color="blue"><font color="blue">indication</font>s</font>;       •     <font color="blue">development</font>s concerning our <font color="blue">collaboration</font> with Roche;       •     our success in establishing <font color="blue">additional</font> <font color="blue"><font color="blue">collaboration</font>s</font>;       •     <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue">United States</font>, Canada and other countries;       •     <font color="blue">development</font>s or <font color="blue">disputes concerning patents</font> or other <font color="blue"><font color="blue">proprietary</font> rights</font>;       •     public concern over <font color="blue">CellCept </font>or any <font color="blue">future products</font>;       •     <font color="blue">litigation</font>;     27       _________________________________________________________________           •     the <font color="blue">departure</font> of <font color="blue">key personnel</font>;       •     <font color="blue">future sales</font> of our <font color="blue">common shares</font>;       •     <font color="blue">variations</font> in our financial results or those of companies that are perceived     to be similar to us;       •     investors’ perceptions of us; and       •     general economic, industry and market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>If there are substantial sales of our <font color="blue">common shares</font>, our <font color="blue">stock price could</font>     decline</td>
    </tr>
    <tr>
      <td>If our <font color="blue">existing <font color="blue">shareholders</font> sell</font> a large number of our <font color="blue">common shares</font> or the     <font color="blue">public market</font> perceives that <font color="blue">existing <font color="blue">shareholders</font> might sell</font> our common     shares, the <font color="blue">market price</font> of our <font color="blue">common shares</font> could decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">executive officer</font>s</font>, <font color="blue">directors</font> and <font color="blue">major <font color="blue">shareholders</font> continue</font> to have     substantial <font color="blue">control over</font> us and will maintain the ability to control all     <font color="blue">matters submitted</font> to <font color="blue">shareholders</font> for approval</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our <font color="blue">directors</font> and <font color="blue"><font color="blue">executive officer</font>s</font>, <font color="blue">together with</font>     their affiliates, beneficially owned the majority of our <font color="blue">outstanding common</font>     shares, including shares subject to <font color="blue">outstanding stock options</font> and warrants</td>
    </tr>
    <tr>
      <td>These <font color="blue">shareholders</font>, acting together, can exercise <font color="blue">significant</font> influence over     all  matters requiring <font color="blue">shareholder approval</font>, including the election of     <font color="blue">directors</font> and any <font color="blue">amendment</font> of our notice of articles or articles</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">concentration</font>  of  <font color="blue">ownership could also</font> have the effect of delaying or     preventing a change in our control</td>
    </tr>
    <tr>
      <td>Our articles, our <font color="blue">shareholder rights</font> plan and certain <font color="blue">Canadian </font>laws could     delay or deter a change of control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">authorized preferred capital stock</font> is available for <font color="blue">issuance from</font> time     to time at the <font color="blue">discretion</font> of our board of <font color="blue">directors</font>, without shareholder     approval</td>
    </tr>
    <tr>
      <td>Our <font color="blue">articles grant</font> our board of <font color="blue">directors</font> the authority, subject     to the <font color="blue">corporate law</font> of British Columbia, to determine or alter the special     rights and <font color="blue">restrictions</font> granted to or <font color="blue">imposed on</font> any <font color="blue">wholly unissued series</font>     of <font color="blue">preferred shares</font>, and <font color="blue">such rights</font> may be superior to those of our common     shares</td>
    </tr>
    <tr>
      <td>Also, pursuant to our <font color="blue">shareholder rights</font> plan, anyone who seeks to acquire     20prca or more of our outstanding <font color="blue">common shares</font> is required to make a bid     <font color="blue">complying with specific provisions</font> of the plan</td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font>on the ability to acquire and hold our <font color="blue">common shares</font> may be     imposed  by the Competition Act (Canada)</td>
    </tr>
    <tr>
      <td>This <font color="blue">legislation</font> permits the     <font color="blue"><font color="blue">Commissioner </font> </font>of  <font color="blue">Competition of Canada </font>to review any <font color="blue">acquisition</font> of a     <font color="blue">significant</font>  interest  in us</td>
    </tr>
    <tr>
      <td>This <font color="blue">legislation</font> grants the <font color="blue"><font color="blue">Commissioner </font> </font>   <font color="blue">jurisdiction</font>  to  challenge  such  an  <font color="blue">acquisition</font> before the <font color="blue"><font color="blue">Canadian </font>    </font>Competition Tribunal if the <font color="blue">Commissioner </font>believes that it would, or would be     likely to, result in a substantial lessening or prevention of <font color="blue">competition</font> in     any  market  in Canada</td>
    </tr>
    <tr>
      <td>The Investment Canada Act (Canada) subjects an     <font color="blue">acquisition</font> of control of a <font color="blue">company by</font> a non-<font color="blue">Canadian </font>to <font color="blue">government</font> review     if the value of our <font color="blue">assets as calculated pursuant</font> to the <font color="blue">legislation</font> exceeds     a <font color="blue">threshold amount</font></td>
    </tr>
    <tr>
      <td>A reviewable <font color="blue">acquisition</font> may not <font color="blue">proceed unless</font> the     <font color="blue">relevant minister</font> is satisfied that the <font color="blue">investment</font> is likely to be a net     benefit to Canada</td>
    </tr>
    <tr>
      <td>Any of the foregoing could prevent or delay a change of control and may     deprive or <font color="blue">limit strategic opportunities</font> for our <font color="blue">shareholders</font> to sell their     shares</td>
    </tr>
    <tr>
      <td>We may be a <font color="blue">passive foreign</font> <font color="blue">investment</font> company for US <font color="blue">tax purposes which</font>     <font color="blue">may negatively affect</font> US investors</td>
    </tr>
    <tr>
      <td>For US <font color="blue">federal income taxation purposes</font>, we will be a <font color="blue">passive foreign</font>     <font color="blue">investment</font> company, or PFIC, if in any <font color="blue">taxable year either</font>: (a) 75prca or more     of our gross <font color="blue">income consists</font> of <font color="blue">passive income</font>; or (b) 50prca or more of the     value of our assets is <font color="blue">attributable</font> to assets that produce, or are held for     the production of, <font color="blue">passive income</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">meet either test</font>, our shares held     by a US person in that year will be PFIC shares for that year and all     <font color="blue">subsequent years</font> in which they are held by that person</td>
    </tr>
    <tr>
      <td>Because in the past     our gross <font color="blue">income consisted mostly</font> of interest, we have been a PFIC in prior     taxable years</td>
    </tr>
    <tr>
      <td>Gain realized     by a US <font color="blue">investor from</font> the sale of PFIC shares is <font color="blue">taxed as ordinary income</font>,     as opposed to <font color="blue">capital gain</font>, and subject to an <font color="blue">interest charge unless</font> the     US person has timely made a <font color="blue">certain tax election</font></td>
    </tr>
    <tr>
      <td>The PFIC rules are <font color="blue">extremely complex</font></td>
    </tr>
    <tr>
      <td>A US person is encouraged to consult     his or her US <font color="blue">tax advisor</font> before making an <font color="blue">investment</font> in our shares</td>
    </tr>
    <tr>
      <td>As a foreign private issuer, we are subject to <font color="blue">different</font> US securities     laws and rules than a domestic US issuer, which may limit the information     <font color="blue">publicly available</font> to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>As a foreign private issuer we are not required to <font color="blue">comply with</font> all the     periodic <font color="blue">disclosure</font> <font color="blue">requirements</font> <font color="blue">of the Securities Exchange Act </font>of 1934 and     therefore there may be less <font color="blue">publicly available</font> information about <font color="blue">Aspreva     </font>than  if  we  were  a US <font color="blue">domestic issuer</font></td>
    </tr>
    <tr>
      <td>In addition, our officers,     <font color="blue">directors</font>, and principal <font color="blue">shareholders</font> are <font color="blue">exempt from</font> the reporting and      &amp;quote short-swing &amp;quote  <font color="blue">profit recovery provisions</font> of Section 16 of the Securities     Exchange Act of 1934 and the <font color="blue">rules thereunder</font></td>
    </tr>
    <tr>
      <td>However, under <font color="blue"><font color="blue">Canadian </font>    </font>provincial  securities  laws,  our  officers,  <font color="blue">directors</font> and principal     <font color="blue">shareholders</font> are required to file reports in <font color="blue">electronic format through</font> the     <font color="blue">System for Electronic Disclosure </font>by Insiders, or SEDI, disclosing changes in     <font color="blue">beneficial ownership</font> of, or control or <font color="blue">direction over</font>, our <font color="blue">common shares</font> and     other securities</td>
    </tr>
    <tr>
      <td>Our <font color="blue">shareholders</font> can <font color="blue">access such</font> reports at www</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________         You may be unable to enforce actions <font color="blue">against us</font>, or certain of our <font color="blue">directors</font>     and officers, under US <font color="blue">federal securities laws</font></td>
    </tr>
    <tr>
      <td>We are a <font color="blue">corporation</font> organized under the laws of British Columbia, Canada</td>
    </tr>
    <tr>
      <td>A     majority of our <font color="blue">directors</font> and officers reside <font color="blue">principally</font> in Canada</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>all or a substantial portion of our assets and the assets of these persons     are <font color="blue">located outside</font> the US, it may not be possible for you to effect     service  of <font color="blue">process within</font> the <font color="blue"><font color="blue">United States</font> </font>upon us or those persons</td>
    </tr>
    <tr>
      <td><font color="blue">Furthermore </font>it may not be possible for you to enforce <font color="blue">against us</font> or them in     the <font color="blue">United States</font>, judgments obtained in US courts based upon the civil     <font color="blue">liability</font> provisions of the US <font color="blue">federal securities laws</font> or other laws of     the US There is doubt as to the <font color="blue">enforceability</font>, in <font color="blue">original actions</font> in     <font color="blue">Canadian </font>courts, of <font color="blue">liabilities</font> based upon the US <font color="blue">federal securities laws</font>     and as to the <font color="blue">enforceability</font> in <font color="blue">Canadian </font>courts of judgments of US courts     obtained in <font color="blue">actions based upon</font> the civil <font color="blue">liability</font> provisions of the US     <font color="blue">federal securities laws</font></td>
    </tr>
    <tr>
      <td>Therefore, it may not be possible to enforce those     actions <font color="blue">against us</font> or certain of our <font color="blue">directors</font> and officers</td>
    </tr>
  </tbody>
</table>